share_log

T2 Biosystems | 8-K: T2 Biosystems Announces Preliminary Third Quarter 2023 Financial Results and FDA 510(k) Submission to Expand the Pathogen Detection on its FDA-Cleared T2Bacteria Panel

SEC ·  Oct 13, 2023 04:32
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.